Neuland Laboratories Ltd. (NEULANDLAB) Share Price Hits 52-Week High
- August 5, 2026
- Posted by: Harsh Piplani
- Category: News
Neuland Laboratories Ltd. Share Price has surged to a fresh 52-week high of Rs 20,100, marking a significant 4.21% increase from the previous close of Rs 19,288.35. This rise has brought the company’s market capitalisation to Rs 25,160.18 crore. The stock opened at Rs 19,252.75 and reached its peak at Rs 20,100, reflecting strong investor interest. The turnover for the day was Rs 5.72 crore with a volume of 2,844 shares traded. This milestone highlights the stock’s robust performance in the healthcare sector.
Neuland Laboratories Ltd. Share Price Today: Price Action Analysis
| Metric | Value |
|---|---|
| Current Price | Rs 20,100 |
| Previous Close | Rs 19,288.35 |
| Today's Change | +Rs 811.65 (+4.21%) |
| Day Open | Rs 19,252.75 |
| Fresh 52-Week High | Rs 20,100 |
| Day Low | Rs 19,252.75 |
| Current Volume | 2,844 |
| Turnover | Rs 5.72 crore |
| Market Capitalisation | Rs 25,160.18 crore |
Neuland Laboratories Ltd. (NEULANDLAB) traded at Rs 20,100. versus the previous close of Rs 19,288.35, a rise of 4.21%. The stock opened at Rs 19,252.75, reached Rs 20,100, touched Rs 19,252.75. Reported volume was 2,844.
Today, Neuland Laboratories Ltd. Share Price opened at Rs 19,252.75 and quickly climbed to a new 52-week high of Rs 20,100. The stock’s previous close was Rs 19,288.35, and it experienced a day change of Rs 811.65, equivalent to a 4.21% increase. The day’s low matched the opening price, indicating a strong upward momentum throughout the trading session. The turnover reached Rs 5.72 crore, with a volume of 2,844 shares, suggesting active participation from investors. This price action underscores the stock’s appeal in the market, setting the stage for further analysis of its fundamentals and sector context.
Neuland Laboratories Ltd. (NEULANDLAB) Fundamental Analysis
| Metric | Value |
|---|---|
| Market Capitalisation | Rs 25,160.18 crore |
| P/E Ratio | 30.21x |
| P/B Ratio | 0.44x |
| ROE | -2.89% |
| ROCE | -0.26% |
Neuland Laboratories Ltd. was valued at a P/E ratio of 30.21x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.
Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.
Sector and Industry Context
| Metric | Value |
|---|---|
| Sector | Healthcare |
| Benchmark Scope | same sector |
| Company P/E Ratio | 30.21x |
| Benchmark Median P/E | 21.71x |
| Benchmark Average P/E | 71.67x |
| Benchmark P/E Range | 0x to 3,385.56x |
| Company P/B Ratio | 0.44x |
| Benchmark Median P/B | 1.9x |
| Company ROE | -2.89% |
| Benchmark Median ROE | 10.75% |
| Company ROCE | -0.26% |
| Benchmark Median ROCE | 13.29% |
| Company Market Capitalisation | Rs 25,160.18 crore |
| Benchmark Median Market Cap | Rs 136.63 crore |
Neuland Laboratories Ltd. (NEULANDLAB) is classified under sector: Healthcare.
Neuland Laboratories Ltd. (NEULANDLAB) has a P/E ratio of 30.21x, which is above the benchmark median of 21.71x, a difference of +39.15%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.
Neuland Laboratories Ltd. (NEULANDLAB) has a ROE of -2.89%, which is below the benchmark median of 10.75%, a difference of -126.88%. Neuland Laboratories Ltd. (NEULANDLAB) has a ROCE of -0.26%, which is below the benchmark median of 13.29%, a difference of -101.96%.
Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.
Peer Comparison
| Company | Symbol | Market Cap (Cr) | P/E | P/B | ROE (%) | ROCE (%) |
|---|---|---|---|---|---|---|
| Dishman Carbogen Amcis Ltd. | DCAL | 2,945.17 | 30.21 | 0.44 | -2.89 | -0.26 |
| Kwality Pharmaceuticals Ltd. | KPL | 2,652.68 | 39.86 | 8.11 | 28.21 | 26.35 |
| Beta Drugs Ltd. | BETA | 2,608.51 | 63.2 | 10 | 18.65 | 22.17 |
| Dr Agarwals Eye Hospital Ltd. | DRAGARWQ | 2,457.9 | 32.25 | 6.65 | -2.6 | 16.92 |
| Sai Parenteral's Ltd. | SAIPARENT | 2,451.51 | 164.6 | 3.04 | 13.9 | 12.97 |
Neuland Laboratories Ltd. (NEULANDLAB) has a P/E ratio of 30.21x compared with the displayed peer median of 39.86x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. Neuland Laboratories Ltd. (NEULANDLAB) has a market capitalisation of Rs 25,160.18 crore. Among the 5 peers shown, 0 have a larger market capitalisation.
Why Investors Are Watching Neuland Laboratories Ltd.
- Neuland Laboratories Ltd. Share Price reached a fresh 52-week high of Rs 20,100.
- Strong price action with a 4.21% increase today.
- Potential undervaluation indicated by a low P/B ratio of 0.44.
- Challenges in profitability with negative ROE and ROCE.
- Significant market cap in the healthcare sector.
About Neuland Laboratories Ltd.
Neuland Laboratories Ltd. is a prominent player in the healthcare sector, focusing on the development and manufacturing of active pharmaceutical ingredients (APIs). The company serves a global clientele, providing high-quality APIs for various therapeutic segments. With a commitment to innovation and excellence, Neuland Laboratories Ltd. continues to expand its product portfolio and enhance its market presence. The company’s strategic initiatives aim to strengthen its position in the competitive pharmaceutical industry.
Track Neuland Laboratories Ltd. Share Price on Univest
Use Neuland Laboratories Ltd. (NEULANDLAB) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.
Investors can track Neuland Laboratories Ltd. Share Price, along with technical indicators, fundamental ratios, shareholding patterns, 52-week levels, and market insights on Univest. Stay informed with real-time data and comprehensive analysis to make well-informed investment decisions.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Frequently Asked Questions
What is the current share price of Neuland Laboratories Ltd.?
Ans. The current share price of Neuland Laboratories Ltd. is Rs 20,100, marking a fresh 52-week high with a 4.21% increase from the previous close. The stock moved 4.21% during the session.
What is the market capitalisation of Neuland Laboratories Ltd.?
Ans. Neuland Laboratories Ltd. has a market capitalisation of Rs 25,160.18 crore, positioning it as a significant entity in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.21x.
What is the P/E ratio of Neuland Laboratories Ltd.?
Ans. Neuland Laboratories Ltd. has a P/E ratio of 30.21, which is above the sector median of 21.71, indicating a relatively higher valuation. The company trades at a P/E ratio of 30.21x.
How does Neuland Laboratories Ltd.'s P/B ratio compare to the sector?
Ans. Neuland Laboratories Ltd.'s P/B ratio of 0.44 is significantly below the sector median of 1.9, suggesting potential undervaluation. The company trades at a P/E ratio of 30.21x. Its P/B ratio is 0.44x.
What are the ROE and ROCE of Neuland Laboratories Ltd.?
Ans. Neuland Laboratories Ltd. has a negative ROE of -2.89% and ROCE of -0.26%, indicating challenges in profitability and capital efficiency. ROE stands at -2.89%. ROCE stands at -0.26%. The relevant peer median ROE is 10.75%.
How does Neuland Laboratories Ltd. compare to its peers?
Ans. Neuland Laboratories Ltd. has a higher market cap than peers like Dishman Carbogen Amcis Ltd. but faces challenges with negative ROE and ROCE. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Beta Drugs Ltd.
What is the significance of Neuland Laboratories Ltd.'s 52-week high?
Ans. The 52-week high of Rs 20,100 signifies strong investor interest and positive market sentiment towards Neuland Laboratories Ltd. The stock moved 4.21% during the session. The intraday range extended from Rs 19,252.75 to Rs 20,100.
